An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

Locally Recurrent Prostate Cancer Clinical Trial

Official title:
An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate. Therapeutic activity will be determined based on changes in PSA levels, PSA velocity, PSA doubling time and tumor burden following treatment.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Locally Recurrent Prostate Cancer
Prostatic Neoplasms

Clinical Trial Details

NCT number	NCT00686088
Study type	Interventional
Source	Sophiris Bio Corp
Contact
Status	Completed
Phase	Phase 2
Start date	February 2008
Completion date	September 2009

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03350529` - MRI Guided Transurethral HIFU for Various Prostate Diseases	N/A
Not yet recruiting	`NCT06202248` - A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer	N/A
Recruiting	`NCT03312972` - Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy	Phase 1/Phase 2
Recruiting	`NCT03073278` - Focal Radiotherapy for Previously Treated Prostate Cancer Patients	N/A